Several clinical studies of the HGF/c-Met pathway in NSCLCs demonstrated that its expression was associated with a poor survival rate of NSCLC patients (Ichimura et al, 1996; Takanami et al, 1996; Siegfried et al, 1997). This evidence concerns the gene HGF and non-small cell lung carcinoma.